Mode
Text Size
Log in / Sign up
N/A N=72 Randomized Prevention

Introvision for Migraine and Headaches

Migraine · Chronic Migraine

Enrolled (actual)
72
Serious AEs
0.0%
Results posted
Apr 2025
Primary outcome: Primary: Number of Headache Days Per Month — 10.6; 10.9 days per month — p=0.63

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Introvision: mental and emotional self-regulation (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Ludwig-Maximilians - University of Munich
Primary completion
Sep 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Headache Days Per Month
10.6; 10.9 0.63
SECONDARY
Headache Intensity
2.0; 2.0
SECONDARY
Acute Medication Per Month
6.3; 5.0 0.004 sig
SECONDARY
Number of Headache Days Per Month in Pooled Groups Analysis Before and 3 Months After Introvision as Parameter for the Efficacy of Introvision
11.7; 9.8 0.003 sig
SECONDARY
Headache Management Self-efficacy Scale-German-short Form (HMSE-G-SF)
21.7; 26.2 0.001 sig
SECONDARY
Headache-Impact Test 6, HIT-6
64.3; 61.4 0.001 sig
SECONDARY
Overall Satisfaction of Patients
45

Summary

To evaluate the effect of Introvision, a mental and emotional self-regulation-technique developed by Angelika C. Wager, as migraine preventative compared to a waiting list group.

Eligibility Criteria

Inclusion Criteria

  • Episodic migraine with at least 5 headache days per month, episodic migraine and tension type headache with at least 5 migraine headache days per month, chronic migraine
  • Stable prophylactic headache medication
  • Stable non-medication headache prophylaxis (sports, relaxation techniques, …)
  • Informed consent

Exclusion Criteria

  • Other causes of headache, symptomatic headaches
  • Other primary headaches such as Cluster headache, trigeminal neuralgia, idiopathic facial pain, new daily persistent headache
  • Severe depression (more than 13 points in the Beck Depression inventory fast screen (BDI-FS)
  • Drug - or alcohol abuse
  • Non-compliance, especially significant missing entries in the headache diaries
  • Active psychosis
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03507400). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search